Karyopharm Offers Updated Selinexor Phase 1b/@ STOMP Myeloma Data Showed 17.8-month PFS and 83% ORR in the BOSTON Multiple Myeloma (MM) Population; 63% ORR in the Overall Study Population
Benzinga Newsdesk